Contributors

Journalist and author Fran Hawthorne has covered health care and business for more than 20 years for the New York Times, Fortune, Worth and Newsday among others. She is also the author of four books, including Inside the FDA, and most recently, Pension Dumping, published in April. In Diverting a Diet Drug, Hawthorne explores how a pharmaceutical company transitioned a weight-loss drug from being prescription-on

Written byThe Scientist
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Journalist and author Fran Hawthorne has covered health care and business for more than 20 years for the New York Times, Fortune, Worth and Newsday among others. She is also the author of four books, including Inside the FDA, and most recently, Pension Dumping, published in April. In Diverting a Diet Drug, Hawthorne explores how a pharmaceutical company transitioned a weight-loss drug from being prescription-only to over the counter. "I was very concerned that drug companies and the FDA would turn the public loose on this so-called 'miracle' drug to treat obesity," she says. "I wanted to follow up to find out what was being done to protect the public."

Eric Smith trained as a statistical physicist, but he says he's done some "relatively serious dabbling" in a large range of scientific areas, including oceanography, microwave engineering, and statistical acoustics. In 2000, Smith joined the Santa Fe Institute to study ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies